Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 7Withdrawn 1

Sponsor Class

OTHER 13INDUSTRY 8NIH 6

Study Type

Observational 4Interventional 4

Sponsor

Cancer Type

Genitourinary 8Lymphoid 1

Conditions

Carcinoma, Renal Cell 8Neoplasms 5Lymphoma, Mantle-Cell 4Breast Neoplasms 4Kidney Neoplasms 3Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma 2Urogenital Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × temsirolimus × Clear all
NCT02184416 2026-02-27

ADONIS

Pfizer

Completed
554 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01210482 2024-09-25

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Pfizer

Completed
1,050 enrolled 9 charts
Genitourinary

Carcinoma, Renal Cell

NCT00631371 2016-04-27

INTORACT

Pfizer

Phase 3 Completed
791 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Urogenital Neoplasms

NCT01367457 2016-04-27

INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

Pfizer

Completed
243 enrolled 12 charts
GenitourinaryLymphoid

Carcinoma, Renal Cell, Lymphoma, Mantle-Cell

NCT00474786 2013-11-21

INTORSECT

Pfizer

Phase 3 Completed
512 enrolled 16 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01781442 2013-05-01

A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

Pfizer

Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT00065468 2012-10-25

ARCC

Pfizer

Phase 3 Completed
626 enrolled 18 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00563147 2011-10-04

A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
28 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡